SCHEMBL6735252

SCHEMBL6735252

N#Cc1ccc(Oc2ccc(NCc3cccnc3)cc2)c(F)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.52
MAPT P10636 1/20 0.52
PABPC1 P11940 1/20 0.52
KMT2A Q03164 1/20 0.52
CYP3A4 P08684 5/20 0.52
CYP2C19 P33261 4/20 0.49
CYP2C9 P11712 1/20 0.49
ALDH1A1 P00352 4/20 0.46
ABCB1 P08183 1/20 0.46
ABCC1 P33527 1/20 0.46
ABCG2 Q9UNQ0 1/20 0.46
LTA4H P09960 1/20 0.46
PDE5A O76074 1/20 0.46
SCN9A Q15858 1/20 0.45
MAPK14 Q16539 1/20 0.45
CYP19A1 P11511 1/20 0.44
CYP1A2 P05177 3/20 0.44
HSD17B10 Q99714 3/20 0.44
CLK4 Q9HAZ1 3/20 0.44
ALOX15 P16050 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6736390 0.90 MEN1 (0.50) MEN1MAPTPABPC1KMT2ACYP3A4
SCHEMBL6836678 0.84 MAPT (0.55) MEN1MAPTPABPC1KMT2ACYP3A4
SCHEMBL6730999 0.82 LTA4H (0.58) MEN1MAPTPABPC1KMT2ACYP3A4
SCHEMBL22530043 0.81 MAPT (0.60) MEN1MAPTPABPC1KMT2ACYP3A4
SCHEMBL10558180 0.80 CYP3A4 (0.68) MEN1MAPTPABPC1KMT2ACYP3A4
SCHEMBL6735876 0.79 MAPK14 (0.68) MEN1MAPTKMT2ACYP3A4CYP2C19
SCHEMBL22530427 0.79 MAPT (0.58) MEN1MAPTPABPC1KMT2ACYP3A4
SCHEMBL28481118 0.77 KDM4E (0.46) MEN1MAPTKMT2AMAPK1
SCHEMBL22530439 0.76 CYP3A4 (0.56) MEN1MAPTPABPC1KMT2ACYP3A4
SCHEMBL22530028 0.76 MAPT (0.54) MEN1MAPTPABPC1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6800651-B2 Potentiators of glutamate receptors ELI LILLY AND COMPANY 2004-10-05 US disclosed
US-20040006114-A1 Potentiators of glutamate receptors ELI LILLY AND COMPANY 2004-01-08 US disclosed
EP-1255735-A2 PYRIDINE DERIVATIVES AS POTENTIATORS OF GLUTAMATE RECEPTORS ELI LILLY AND COMPANY (US) 2002-11-13 EP disclosed
WO-2001056990-A2 PYRIDINE DERIVATES AS POTENTIATORS OF GLUTAMATE RECEPTORS ELI LILLY AND COMPANY (US) 2001-08-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040006114-A1 Potentiators of glutamate receptors GRM1, GRIN1, GRM2 MEN1 2793/4885MAPT 3885/4885PABPC1 3956/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.